Maurizio Rossini

Summary

Affiliation: University of Verona
Country: Italy

Publications

  1. ncbi Vitamin D and rheumatic diseases
    M Rossini
    Rheumatology Unit, University of Verona
    Reumatismo 66:153-70. 2014
  2. ncbi Medication use before and after hip fracture: a population-based cohort and case-control study
    Maurizio Rossini
    Rheumatology Unit, Department of Medicine, University of Verona, Policlinico Borgo Roma, Piazzale Scuro, 10, 37134, Verona, Italy
    Drugs Aging 31:547-53. 2014
  3. ncbi Bone involvement and osteoporosis in mastocytosis
    Maurizio Rossini
    University of Verona, Policlinico Borgo Roma, Piazzale Scuro, 10, Verona 37134, Italy Electronic address
    Immunol Allergy Clin North Am 34:383-96. 2014
  4. pmc Vitamin D deficiency in rheumatoid arthritis: prevalence, determinants and associations with disease activity and disability
    Maurizio Rossini
    Rheumatology Unit, University of Verona, Piazzale Stefani 1, 37124 Verona, Italy
    Arthritis Res Ther 12:R216. 2010
  5. pmc Profile of bazedoxifene/conjugated estrogens for the treatment of estrogen deficiency symptoms and osteoporosis in women at risk of fracture
    Maurizio Rossini
    Department of Medicine, Rheumatology Unit, University of Verona, Italy
    Drug Des Devel Ther 7:601-10. 2013
  6. doi Acute phase response after zoledronic acid is associated with long-term effects on white blood cells
    Maurizio Rossini
    Rheumatology Section, Department of Medicine, University of Verona, Italy
    Calcif Tissue Int 93:249-52. 2013
  7. ncbi Regional differences of vitamin D deficiency in rheumatoid arthritis patients in Italy
    M Rossini
    Rheumatology Unit, University of Verona, Italy
    Reumatismo 65:113-20. 2013
  8. doi Osteoporosis treatment: why ibandronic acid?
    Maurizio Rossini
    University of Verona, Department of Medicine, Rheumatology Section, Policlinico Borgo Roma, Piazzale Scuro, 10 37134, Verona, Italy
    Expert Opin Pharmacother 14:1371-81. 2013
  9. doi Long-term effects of amino-bisphosphonates on circulating γδ T cells
    Maurizio Rossini
    Rheumatology Unit, Department of Medicine, University of Verona, Policlinico Borgo Roma, Piazzale Scuro, 10, 37134, Verona, Italy
    Calcif Tissue Int 91:395-9. 2012
  10. ncbi Short-term effects on bone turnover markers of a single high dose of oral vitamin D₃
    Maurizio Rossini
    Rheumatology Unit, Department of Medicine, University of Verona, Policlinico Borgo Roma, Piazzale Scuro, 10, 37134 Verona, Italy
    J Clin Endocrinol Metab 97:E622-6. 2012

Detail Information

Publications49

  1. ncbi Vitamin D and rheumatic diseases
    M Rossini
    Rheumatology Unit, University of Verona
    Reumatismo 66:153-70. 2014
    ..This review aims to provide an overview of the latest evidence concerning the relationship between vitamin D and the most relevant rheumatic diseases. ..
  2. ncbi Medication use before and after hip fracture: a population-based cohort and case-control study
    Maurizio Rossini
    Rheumatology Unit, Department of Medicine, University of Verona, Policlinico Borgo Roma, Piazzale Scuro, 10, 37134, Verona, Italy
    Drugs Aging 31:547-53. 2014
    ..Osteoporosis, together with age, is the main risk factor for hip fracture, the incidence of which has also been associated with an increased risk of falling or co-morbidities and related pharmacological treatments...
  3. ncbi Bone involvement and osteoporosis in mastocytosis
    Maurizio Rossini
    University of Verona, Policlinico Borgo Roma, Piazzale Scuro, 10, Verona 37134, Italy Electronic address
    Immunol Allergy Clin North Am 34:383-96. 2014
    ..The bone turnover markers indicate the involvement of complex bone metabolism in mastocytosis-related manifestations. Bisphosphonates represent the first-line treatment for osteoporosis-related mastocytosis. ..
  4. pmc Vitamin D deficiency in rheumatoid arthritis: prevalence, determinants and associations with disease activity and disability
    Maurizio Rossini
    Rheumatology Unit, University of Verona, Piazzale Stefani 1, 37124 Verona, Italy
    Arthritis Res Ther 12:R216. 2010
    ....
  5. pmc Profile of bazedoxifene/conjugated estrogens for the treatment of estrogen deficiency symptoms and osteoporosis in women at risk of fracture
    Maurizio Rossini
    Department of Medicine, Rheumatology Unit, University of Verona, Italy
    Drug Des Devel Ther 7:601-10. 2013
    ....
  6. doi Acute phase response after zoledronic acid is associated with long-term effects on white blood cells
    Maurizio Rossini
    Rheumatology Section, Department of Medicine, University of Verona, Italy
    Calcif Tissue Int 93:249-52. 2013
    ..The mechanism leading to the observed decrease of circulating lymphocytes and eosinophils remains unclear, but our observation opens a new frontier for the understanding of the immunoeffects of N-BPs...
  7. ncbi Regional differences of vitamin D deficiency in rheumatoid arthritis patients in Italy
    M Rossini
    Rheumatology Unit, University of Verona, Italy
    Reumatismo 65:113-20. 2013
    ..In RA Italian patients there are significant regional differences in the prevalence of vitamin D deficiency explained by different BMI, and sun exposure time, and inversely associated with disease activity and disability scores. ..
  8. doi Osteoporosis treatment: why ibandronic acid?
    Maurizio Rossini
    University of Verona, Department of Medicine, Rheumatology Section, Policlinico Borgo Roma, Piazzale Scuro, 10 37134, Verona, Italy
    Expert Opin Pharmacother 14:1371-81. 2013
    ..In this article, we have summarized the specific evidence on ibandronic acid (or ibandronate) efficacy, tolerability, and feasibility acquired from trials and clinical use...
  9. doi Long-term effects of amino-bisphosphonates on circulating γδ T cells
    Maurizio Rossini
    Rheumatology Unit, Department of Medicine, University of Verona, Policlinico Borgo Roma, Piazzale Scuro, 10, 37134, Verona, Italy
    Calcif Tissue Int 91:395-9. 2012
    ..Other clinical implications of this sustained effect of N-BPs on immune-regulatory cells might be important...
  10. ncbi Short-term effects on bone turnover markers of a single high dose of oral vitamin D₃
    Maurizio Rossini
    Rheumatology Unit, Department of Medicine, University of Verona, Policlinico Borgo Roma, Piazzale Scuro, 10, 37134 Verona, Italy
    J Clin Endocrinol Metab 97:E622-6. 2012
    ....
  11. doi Long-term effects of neridronate and its discontinuation in patients with primary hyperparathyroidism
    Maurizio Rossini
    Rheumatology Unit, Department of Medicine, University of Verona, OCM Borgo Trento, P le Stefani 1, 37126, Verona, Italy
    Calcif Tissue Int 89:21-8. 2011
    ..The marked increases in serum PTH levels, particularly in subjects with low 25OHD levels, persist after treatment discontinuation and this raises the suspicion that this might reflect a worsening of PHPT...
  12. doi Relationship of focal erosions, bone mineral density, and parathyroid hormone in rheumatoid arthritis
    Maurizio Rossini
    Rheumatology Unit, Azienda Ospedaliera Universitaria Integrata, Piazzale Stefani 1, 37126 Verona, Italy
    J Rheumatol 38:997-1002. 2011
    ..To investigate the relationship among focal bone erosions and bone mineral density (BMD), 25(OH) vitamin D (25OHD), and parathyroid hormone (PTH) values in patients with rheumatoid arthritis (RA)...
  13. ncbi [Risk factors for hip fracture in elderly persons]
    M Rossini
    Centro Regione Veneto Specializzato per l Osteoporosi, U O Reumatologia, Azienda Ospedaliera Universitaria Integrata di Verona, Verona, Italia
    Reumatismo 62:273-82. 2010
    ..The aim of this observational study, promoted by the Health Authorities of the Regione Veneto (Italy), is to assess the prevalence of the most relevant environmental and individual risk factors in subjects with a recent hip fracture...
  14. doi Once-monthly oral ibandronate in postmenopausal osteoporosis: translation and updated review
    Maurizio Rossini
    Rheumatology Unit, University Hospital of Verona, Verona 37126, Italy
    Clin Ther 31:1497-510. 2009
    ..New drugs or treatment regimens that reduce the risk for osteoporotic fractures and make the treatment of osteoporosis more convenient and suitable for patients are needed...
  15. doi Bone mineral density, bone turnover markers and fractures in patients with indolent systemic mastocytosis
    Maurizio Rossini
    Rheumatology Section, Department of Medicine, University of Verona, Italy
    Bone 49:880-5. 2011
    ..We systematically assessed bone mineral density (BMD), bone turnover markers (BTM), and fractures in a large cohort of patients with Indolent Systemic Mastocytosis (ISM)...
  16. pmc Capacitively coupled electric field for pain relief in patients with vertebral fractures and chronic pain
    Maurizio Rossini
    Rheumatology Unit, Department of Biomedical and Surgical Sciences, University of Verona, OCM Borgo Trento, P Le Stefani, 1, 37126 Verona, Italy
    Clin Orthop Relat Res 468:735-40. 2010
    ..We interpret these findings as suggesting capacitive coupling electrical stimulation controls pain in some patients and reduces the use of NSAIDs...
  17. doi Sclerostin and DKK1 in primary hyperparathyroidism
    Ombretta Viapiana
    Unit of Rheumatology, University of Verona, P le Scuro 10, 37134, Verona, Italy
    Calcif Tissue Int 92:324-9. 2013
    ..Further studies are warranted in order to verify whether the balance between these two opposite effects on Wnt function might help explain the variable bone involvement among patients with PHPT...
  18. doi Dose-dependent short-term effects of single high doses of oral vitamin D(3) on bone turnover markers
    Maurizio Rossini
    Rheumatology Unit, Department of Medicine, University of Verona, Policlinico Borgo Roma, Piazzale Scuro, 10, 37134, Verona, Italy
    Calcif Tissue Int 91:365-9. 2012
    ..Our results indicate that the use of a vitamin D bolus exceeding 100,000 IU may be associated with acute increases of sCTX...
  19. doi Sclerostin and DKK1 in postmenopausal osteoporosis treated with denosumab
    Davide Gatti
    Unit of Rheumatology, University of Verona, Verona, Italy
    J Bone Miner Res 27:2259-63. 2012
    ..This latter observation might explain the continuous increase over 5 years in BMD observed during treatment of postmenopausal osteoporosis with denosumab...
  20. ncbi Marked increases in bone mineral density and biochemical markers of bone turnover in patients with anorexia nervosa gaining weight
    Ombretta Viapiana
    Department of Rheumathology, University of Verona, Valeggio Hospital, 37067 Valeggio S Mincio, Verona, Italy
    Bone 40:1073-7. 2007
    ..If weight is maintained, the overall improvement approach 1 SD within 1 year. The changes in both weight and BMD are correlated with improvements in bone formation markers and diminutions in a marker of bone resorption...
  21. doi Insulin-like growth factor-1 is associated with bone formation markers, PTH and bone mineral density in healthy premenopausal women
    Silvano Adami
    Rheumatology Unit, Dpt of Scienze biomediche e chirurgiche, University of Verona, Verona, Italy
    Bone 46:244-7. 2010
    ..In conclusion, in this study we provide evidence of an association between the age-related decline in IGF-I with the progressive decrease in bone formation markers in premenopausal women...
  22. ncbi Intravenous bisphosphonate therapy increases radial width in adults with osteogenesis imperfecta
    Davide Gatti
    Rheumatologic Rehabilitation, University of Verona, Verona, Italy
    J Bone Miner Res 20:1323-6. 2005
    ..Neridronate therapy in adult patients with OI significantly increases the cross-sectional area of the proximal radius. This observation may provide an additional explanation for the antifracture efficacy of bisphosphonates...
  23. ncbi Teriparatide treatment in adult patients with osteogenesis imperfecta type I
    Davide Gatti
    Rheumatology Unit, Department of Medicine, University of Verona, Piazzale Stefani 1, 37126, Verona, Italy
    Calcif Tissue Int 93:448-52. 2013
    ..Our results open the possibility to develop TPD for the treatment of adult type I OI, but particularly for the lack of a control group, a properly designed controlled study is warranted...
  24. ncbi Determinants and effects of vitamin D supplementation on serum 25-hydroxy-vitamin D levels in patients with rheumatoid arthritis
    Massimo Varenna
    Rheumatology Unit, Istituto Ortopedico Gaetano Pini, Milano, Italy
    Clin Exp Rheumatol 30:714-9. 2012
    ..This study evaluated factors related with the prescription of vitamin D supplements in RA patients and variables influencing the achievement of adequate vitamin D levels...
  25. doi Bisphosphonate treatment of postmenopausal osteoporosis is associated with a dose dependent increase in serum sclerostin
    Davide Gatti
    Rheumatology Unit, Department of Medicine, University of Verona, Italy
    Bone 50:739-42. 2012
    ..This might suggest that Wnt signaling may play a role in the coupling between resorption and formation...
  26. ncbi Determinants of bone turnover markers in healthy premenopausal women
    Silvano Adami
    Rheumatology Unit, University of Verona, Ospedale di Valeggio, Valeggio, Verona, Italy
    Calcif Tissue Int 82:341-7. 2008
    ..New normative ranges for serum OC, CTX, and P1NP were identified; and our findings in general impose a redefinition of the criteria for establishing the normal ranges for BTMs...
  27. ncbi Physical activity and bone turnover markers: a cross-sectional and a longitudinal study
    Silvano Adami
    Rheumatology Unit, Ospedale di Valeggio, University of Verona, 37067, Valeggio, Verona, Italy
    Calcif Tissue Int 83:388-92. 2008
    ..In conclusion, both the cross-sectional and the longitudinal parts of our study demonstrate that even minor changes in physical activity are associated with a clear effect on bone formation markers...
  28. doi The waning of teriparatide effect on bone formation markers in postmenopausal osteoporosis is associated with increasing serum levels of DKK1
    Davide Gatti
    University of Verona, Rheumatology Unit, Valeggio Hospital, Via Ospedale, Valeggio 37067, Verona, Italy
    J Clin Endocrinol Metab 96:1555-9. 2011
    ..TPD is thought to stimulate bone formation by down-regulating the expression of specific Wnt antagonists, such as of sclerostin and Dickkopf-1 (DKK1)...
  29. ncbi Intravenous neridronate in children with osteogenesis imperfecta: a randomized controlled study
    Davide Gatti
    Department of Rheumatology, University of Verona, Verona, Italy
    J Bone Miner Res 20:758-63. 2005
    ..These results are associated with a significant decrease in the risk of clinical fractures...
  30. doi Bisphosphonates vs infliximab in ankylosing spondylitis treatment
    Ombretta Viapiana
    Policlinico GB Rossi, Piazzale Ludovico Scuro 10, 37134 Verona, Italy
    Rheumatology (Oxford) 53:90-4. 2014
    ..The objective of this study was to evaluate if the anti-inflammatory properties of bisphosphonates and their effect on bone turnover could be useful in the treatment of AS...
  31. doi Intramuscular neridronate in postmenopausal women with low bone mineral density
    Silvano Adami
    Rheumatology Unit, Ospedale di Valeggio, University of Verona, 37067, Valeggio, Verona, Italy
    Calcif Tissue Int 83:301-7. 2008
    ..The results of this study indicate that IM neridronate might be of value for patients intolerant to oral bisphosphonates and unwilling or unable to undergo intravenous infusion of bisphosphonates...
  32. ncbi Treatment of complex regional pain syndrome type I with neridronate: a randomized, double-blind, placebo-controlled study
    Massimo Varenna
    Rheumatology Unit, Ospedale G Pini, Milan, Italy
    Rheumatology (Oxford) 52:534-42. 2013
    ..The aim of this multi-centre, randomized, double-blind placebo-controlled trial was to test the efficacy of the amino-bisphosphonate neridronate in patients with CRP-I...
  33. doi Circulating γδ T cells and the risk of acute-phase response after zoledronic acid administration
    Maurizio Rossini
    Rheumatology Unit, Department of Medicine, University of Verona, Verona, Italy
    J Bone Miner Res 27:227-30. 2012
    ..In conclusion, the results of this study indicate that the number of circulating γδ T cells, together with age, are important determinant of the occurrence of APR after intravenous infusion of ZOL and possibly of any other N-BPs...
  34. ncbi Bone turnover markers in patients with osteogenesis imperfecta
    Vania Braga
    Rheumatology Unit, University of Verona, Valeggio S M, Italy
    Bone 34:1013-6. 2004
    ..These results provide a strong rational for the use of anti-resorbing agent in OI...
  35. doi Pharmacokinetic evaluation of bazedoxifene for the treatment of osteoporosis
    Davide Gatti
    University of Verona, Department of Medicine, Rheumatology Unit, Piazzale Stafani 1, 37126 Verona, Italy
    Expert Opin Drug Metab Toxicol 9:883-92. 2013
    ....
  36. ncbi Relationship between serum parathyroid hormone, vitamin D sufficiency, age, and calcium intake
    Silvano Adami
    Rheumatologic Rehabilitation, University of Verona, Italy
    Bone 42:267-70. 2008
    ..In elderly individuals not taking calcium supplements in order to keep serum PTH levels strictly within the normal range 25(OH)D serum levels should be maintained above ca. 120 nMol/L...
  37. doi Allergy and the bone: unexpected relationships
    Davide Gatti
    Rheumatologic Department, University of Verona, Verona, Italy
    Ann Allergy Asthma Immunol 107:202-6. 2011
    ..To examine the relationships between allergy and bone metabolism as represented by the effects of antihistamines and leukotriene modifiers on bone resorption and formation...
  38. doi Densitometric threshold and vertebral fractures in heart transplant patients
    Luca Dalle Carbonare
    Department of Medicine, Clinic of Internal Medicine, Section D, University of Verona, Verona, Italy
    Transplantation 92:106-11. 2011
    ..The aim of our study was to evaluate osteoporosis and fracture prevalence, bone metabolism, and the effect of immunosuppressant agents on bone after heart transplantation...
  39. doi Treatment thresholds for osteoporosis and reimbursability criteria: perspectives associated with fracture risk-assessment tools
    Silvano Adami
    Rheumatology Unit, Department of Medicine, University of Verona, Policlinico Borgo Roma, Piazzale Scuro, 37134, Verona, Italy
    Calcif Tissue Int 93:195-200. 2013
    ..Here, we elaborate an algorithm to convert vertebral and nonvertebral fractures to the "major fractures" of FRAX, and this allows a cost-effectiveness assessment for each drug. ..
  40. doi Intra-articular clodronate for the treatment of knee osteoarthritis: dose ranging study vs hyaluronic acid
    Maurizio Rossini
    Rheumatology Unit, University of Verona, Verona, Italy
    Rheumatology (Oxford) 48:773-8. 2009
    ..In this Phase 2 randomized, partially blind clinical trial, we tested the efficacy of IA clodronate vs HA in patients with primary KOA...
  41. ncbi Prevalence and incidence of rheumatoid arthritis in Italy
    Maurizio Rossini
    Rheumatology Section, Department of Medicine, University of Verona, Policlinico GB Rossi, 37124, Verona, Italy
    Rheumatol Int 34:659-64. 2014
    ..With advancing age, the female/male ratio declines to about one. ..
  42. doi Involvement of WNT/β-catenin signaling in the treatment of osteoporosis
    Maurizio Rossini
    Department of Medicine, Rheumatology Section, Policlinico Borgo Roma, University of Verona, Piazzale Scuro, 10, 37134, Verona, Italy
    Calcif Tissue Int 93:121-32. 2013
    ..Inactivating monoclonal antibodies against SOST appears to be the most attractive strategy because SOST is the only component of the WNT pathway expressed almost exclusively by osteocytes. ..
  43. ncbi The volumetric bone density and cortical thickness in adult patients affected by osteogenesis imperfecta
    Davide Gatti
    Riabilitazione Reumatologica, Universita di Verona, University Hospital Valeggio S M, Verona, Italy
    J Clin Densitom 6:173-7. 2003
    ..In conclusion, it appears that the most obvious defect in adults with OI is the inability to acquire an adequate thickness of the cortices of long bone and to achieve or maintain normal trabecular density...
  44. pmc Clinical development of neridronate: potential for new applications
    Davide Gatti
    Rheumatology Unit, Department of Medicine, University of Verona, Verona, Italy
    Ther Clin Risk Manag 9:139-47. 2013
    ..We will focus in particular on the latest evidence of the effect of neridronate on treatment of complex regional pain syndrome type I...
  45. ncbi The genetic background of osteoporosis in cystic fibrosis: association analysis with polymorphic markers in four candidate genes
    Carlo Castellani
    Cystic Fibrosis Center, Pediatric Department, Azienda Ospedaliera, Verona, Italy
    J Cyst Fibros 5:229-35. 2006
    ..Reduced Bone Mass Density (BMD) is frequent in Cystic Fibrosis (CF). Potentially, other genes than the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) gene may contribute to the bone phenotype variability in CF patients...
  46. doi Osteoporosis treatment and fracture incidence: the ICARO longitudinal study
    S Adami
    Rheumatology Department, University of Verona, Valeggio Sul Mincio Hospital VR, 37067 Valeggio S Mincio, Verona, Italy
    Osteoporos Int 19:1219-23. 2008
    ..5%/year. This incidence is considerably higher than that observed in randomized clinical trials...
  47. pmc Evidence of sustained vertebral and nonvertebral antifracture efficacy with ibandronate therapy: a systematic review
    Silvano Adami
    Rheumatology Unit, University of Verona, Verona, Italy
    Ther Adv Musculoskelet Dis 3:67-79. 2011
    ..The antifracture efficacy of ibandronate at vertebral and nonvertebral sites was assessed...
  48. pmc The initiative on hip fractures of the Veneto Region
    Maurizio Rossini
    Osteoporosis Centers, Veneto Region, Italy, Integrated University Hospital of Verona, Verona, Italy
    Clin Cases Miner Bone Metab 9:45-9. 2012
    ..to assess the prevalence of the most relevant environmental and individual risk factors in subjects with a recent hip fracture was the aim of this observational study promoted by the Health Authorities of the Regione Veneto (Italy)...
  49. ncbi Rosiglitazone therapy is associated with major clinical improvements in a patient with fibrodysplasia ossificans progressiva
    Davide Gatti
    University of Verona, Rheumatology Unit, Valeggio, Verona, Italy
    J Bone Miner Res 25:1460-2. 2010
    ..This case report seems to suggest that rosiglitazone therapy, possibly in association with small doses of prednisone, is associated with important clinical improvements in patients with FOP...